PON2’s ability to confer chemoresistance is particularly evident in renal cell carcinoma and melanoma, where its downregulation sensitizes cells to CDDP and 5-FU (Campagna et al. 2020; Schiavoni et al. 2024). Here, PON2 is linked to hereditary clear cell renal cell carcinoma.